Targeted therapies for myeloproliferative neoplasms Review
| Authors: | Li, B.; Rampal, R. K.; Xiao, Z. |
| Review Title: | Targeted therapies for myeloproliferative neoplasms |
| Abstract: | The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivotal moment in the treatment of MPNs, representing the first targeted treatment in this field. Despite a weak effect on the cause of the disease itself in MPNs, ruxolitinib improves the clinical state of patients and increases survival in myelofibrosis. In parallel, other JAK inhibitors with potential for pathologic and molecular remissions, less myelosuppression, and with greater selectivity for JAK1 or JAK2, and the ability to overcome JAK inhibitor persistence are in various stages of development. Moreover, many novel classes of targeted agents continue to be investigated in efforts to build on the progress made with ruxolitinib. This article will discuss some of the advances in the targeted therapy in this field in recent years and explore in greater detail some of the most advanced emerging agents as well as those with greatest potential. © 2019 The Author(s). |
| Keywords: | survival; mitogen activated protein kinase; myelofibrosis; unclassified drug; histone deacetylase inhibitor; hydroxyurea; janus kinase 2; review; alpha interferon; nuclear magnetic resonance imaging; cd34 antigen; stat1 protein; quality of life; anemia; thrombocytopenia; hemoglobin; chronic myeloid leukemia; protein p53; pneumonia; algorithm; splenomegaly; lymphoma; urinary tract infection; natural killer cell; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; panobinostat; azacitidine; tuberculosis; myeloproliferative neoplasm; thrombocytosis; protein mdm2; clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); givinostat; janus kinase 1; myeloproliferative neoplasms; decitabine; gandotinib; momelotinib; pacritinib; ruxolitinib; human; priority journal; pembrolizumab; fedratinib; bromodomain inhibitor; guadecitabine; tagraxofusp; targeting therapy; cyt38; idasanutlin; ilginatinib; itacitinib; parsaclisib; protein mdm2 inhibitor; umbralisib |
| Journal Title: | Biomarker Research |
| Volume: | 7 |
| ISSN: | 2050-7771 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2019-07-16 |
| Start Page: | 15 |
| Language: | English |
| DOI: | 10.1186/s40364-019-0166-y |
| PROVIDER: | scopus |
| PMCID: | PMC6636147 |
| PUBMED: | 31346467 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 4 September 2019 -- Source: Scopus |
